Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000509

Desogestrel

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

13-Ethyl-11-methylene-18,19-dinor-17α-4-pregnen-20-yn-17-ol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C22H30O
Número de CAS:
54024-22-5
Peso molecular:
310.47
Número MDL:
MFCD00869346
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329830992
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

desogestrel

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

Clave InChI

RPLCPCMSCLEKRS-BPIQYHPVSA-N

Información sobre el gen

human ... PGR(5241)

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Desogestrel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000510

Desogestrel, European Pharmacopoeia (EP) Reference Standard

1173268

Etonogestrel, United States Pharmacopeia (USP) Reference Standard

1173235

Desogestrel, United States Pharmacopeia (USP) Reference Standard

1173257

Desogestrel Related Compound B, United States Pharmacopeia (USP) Reference Standard

1173246

Desogestrel Related Compound A, United States Pharmacopeia (USP) Reference Standard

1173279

Desogestrel Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP816

Etonogestrel, British Pharmacopoeia (BP) Reference Standard

BP817

Desogestrel impurity E, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palabra de señalización

Danger

Frases de peligro

H360FD,H410

Clasificaciones de peligro

Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

H D McClamrock et al.
American journal of obstetrics and gynecology, 168(3 Pt 2), 1021-1028 (1993-03-01)
A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at contraceptive doses. Desogestrel is rapidly and completely metabolized in the liver and gut wall to 3-keto-desogestrel, which is the active
K Fotherby
Contraception, 51(1), 3-12 (1995-01-01)
The clinical experience with a combined oral contraceptive (COC) containing 150 micrograms desogestrel and 30 micrograms ethinylestradiol is reviewed. Fourteen clinical trials have been reported involving over 44,000 women for more than 190,000 cycles. None of the 17 pregnancies which
D Shoupe
American journal of obstetrics and gynecology, 168(3 Pt 2), 1041-1047 (1993-03-01)
Associated with progesterone and the synthetic progestins used in oral contraceptives is a dose-dependent impairment of carbohydrate metabolism. It is well known that in the general population hyperinsulinemia and alterations in glucose metabolism are significant risk factors for the development
Giuseppe Benagiano et al.
Annals of the New York Academy of Sciences, 997, 163-173 (2003-12-03)
Progestin-only minipills have been available for over three decades, yet their use has been limited, because of a documented lower efficacy when compared to pills that combine estrogen and progestin. The availability of a new low-dose progestin-only minipill containing 75
P G Stubblefield
American journal of obstetrics and gynecology, 168(3 Pt 2), 1047-1052 (1993-03-01)
Epidemiologic research has shown that current low-dose estrogen oral contraceptives are associated with a low risk of vascular events (e.g., myocardial infarction, stroke, and venous thrombosis or thromboembolism). Yet questions still persist about the effects of low-dose oral contraceptives on
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico